Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement Statistical Measurement [Domain] Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Customer [Axis] Customer [Axis] Segment Reporting [Abstract] Schedule of Financial Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock Common Stock, Value, Issued Revenue Recognition and Deferred Revenue [Abstract] Restatement Determination Date Restatement Determination Date Maturities and sales of investments Proceeds from Sale, Maturity and Collection of Investments Credit to prepaid expenses and other current assets Collaborative Arrangement, Receivable Collaborative Arrangement, Receivable Potential near-term preclinical milestones Collaborative Arrangement, Potential Near-Term Preclinical Milestones Payment To Be Received Maximum Maximum Potential Near-Term Preclinical Milestones Payment To Be Received Under Collaborative Agreement Amendment Flag Amendment Flag Restructuring, long-lived assets impairment and related charges, net Restructuring, long-lived assets impairment and related charges, net Restructuring Costs and Asset Impairment Charges CURRENT LIABILITIES: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Number of oncology TCEs Asset Acquisition, Number Of Early Clinical Stage Oncology TCEs Asset Acquisition, Number Of Early Clinical Stage Oncology TCEs Gross Unrealized Holding Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Asset-backed securities Asset-Backed Securities [Member] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Unused grant funds returned Grant Agreement, Unused Grant Funds Returned Grant Agreement, Unused Grant Funds Returned PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Asset Acquisition [Axis] Asset Acquisition [Axis] Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Accrued liabilities and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Weighted-average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic (Accretion of discounts) amortization of premiums on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Long-term investments Long-Term Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Total net unrealized gains (losses) recorded in accumulated other comprehensive loss Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Sales Agreement Sales Agreement [Member] Sales agreement. Entity Address, City or Town Entity Address, City or Town Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Proceeds from issuance of common stock under ESPP Proceeds from Stock Plans Level 2 Fair Value, Inputs, Level 2 [Member] Other income: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] U.S. UNITED STATES Upfront payments Collaborative Arrangement, Amount Of Upfront Payment Collaborative Arrangement, Amount Of Upfront Payment Subsequent Event Type [Axis] Subsequent Event Type [Axis] Vesting of restricted common stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross License and collaboration revenue License And Collaboration Revenue [Member] License And Collaboration Revenue New Accounting Pronouncement Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Maximum further development, regulatory and commercial milestones Collaborative Arrangement, Maximum Further Development, Regulatory And Commercial Milestones Payment To Be Received Maximum Maximum Further Development, Regulatory And Commercial Milestones Payment To Be Received Under Collaborative Agreement Schedule of Segment Reporting Information, by Segment Segment Reporting [Table Text Block] Astellas Astellas Pharma Inc. [Member] Astellas Pharma Inc. Use of Estimates Use of Estimates, Policy [Policy Text Block] Total other comprehensive (loss) income Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Changes in Estimated Fair Value of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent consideration liability NONCASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash (used in) provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Unrecognized tax benefits Unrecognized Tax Benefits Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Asset acquisition, period for execution of transaction (in years) Asset Acquisition, Period For Execution Of Transaction Asset Acquisition, Period For Execution Of Transaction Premium received Underlying shares, Premium received Underlying shares, Premium received Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Changes in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Operating lease liabilities, current Operating Lease, Liability, Current Total segment and consolidated revenue Revenue From Contract With Customer, Excluding Assessed Tax, Net Revenue From Contract With Customer, Excluding Assessed Tax, Net Segments Segment Reporting, Policy [Policy Text Block] Schedule of Property and Equipment, Net Property, Plant, and Equipment [Table Text Block] HDV Manufacturing Agreement HDV Manufacturing Agreement [Member] HDV Manufacturing Agreement Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Closing stock price (in USD per share) Closing stock price Closing stock price Common stock, shares purchased, aggregate purchase price Common Stock, Shares Purchased , Aggregate Purchase Price Common Stock, Shares Purchased , Aggregate Purchase Price TOTAL LIABILITIES Liabilities Trading Symbol Trading Symbol Discount rate Measurement Input, Discount Rate [Member] Aggregate Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Geographical [Domain] Geographical [Domain] Purchases of long-lived assets Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Business Combination, Contingent Consideration, Type Business Combination, Contingent Consideration, Type [Axis] Oncology Program Oncology Program [Member] Oncology Program Asset Class Asset Class [Domain] CASH FLOWS FROM OPERATING ACTIVITIES: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Humabs Humabs Biomed S A [Member] Humabs Biomed SA. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Useful life (in years) Property, Plant, and Equipment, Useful Life Underlying Security Market Price Change Underlying Security Market Price Change, Percent VIR‑5500 Program License VIR‑5500 Program License [Member] VIR‑5500 Program License U.S. government treasuries US Treasury Securities [Member] Potential additional future development, regulatory and sales milestone payments, maximum Collaborative Arrangement, Maximum Future Development, Regulatory And Sales Milestones Payments, Additional Amount Collaborative Arrangement, Maximum Future Development, Regulatory And Sales Milestones Payments, Additional Amount Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Financial Support to Nonconsolidated Legal Entity Financial Support to Nonconsolidated Legal Entity [Axis] Restricted Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Maximum future clinical, regulatory, and sales milestone to be received Maximum Future Clinical, Regulatory And Sales Milestone To Be Received Maximum Future Clinical, Regulatory And Sales Milestone To Be Received All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Payments received from collaborative arrangements Payments Received From Collaborative Arrangements Payments Received From Collaborative Arrangements Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Reconciliation to cash, cash equivalents and investments on condensed consolidated balance sheet Reconciliation To Cash, Cash Equivalents And Investments On Consolidated Balance Sheet [Abstract] Reconciliation To Cash, Cash Equivalents And Investments On Consolidated Balance Sheet Commercial Milestones Commercial Milestones [Member] Commercial milestones. Depreciation expenses Depreciation Antidilutive Securities Antidilutive Securities [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Astellas Agreements Astellas Agreements [Member] Astellas Agreements RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS TO THE CONDENSED CONSOLIDATED BALANCE SHEETS: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Operating right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Risk-free interest rate, maximum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Global development costs shared (as a percent) Collaborative Arrangement, Global Development Cost Sharing Percentage Collaborative Arrangement, Global Development Cost Sharing Percentage Segment Reporting Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date External costs (as a percent) Percentage Of External Costs Percentage Of External Costs Income Statement Location Location, Statement of Income, Balance [Axis] Restricted cash and cash equivalents Minus: Restricted cash equivalents invested in money market funds Restricted Cash and Cash Equivalent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aggregate Fair Value Cash and Cash Equivalents, Fair Value Disclosure TOTAL STOCKHOLDERS’ EQUITY Equity, Including Portion Attributable to Noncontrolling Interest Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Public offering issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common stock, shares issued, fair market value Common Stock, Shares Issued, Fair Market Value Common Stock, Shares Issued, Fair Market Value Issuance of common stock related to a follow-on public offering, net of issuance costs Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Sale of stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Exercise Price Award Exercise Price CASH FLOWS FROM INVESTING ACTIVITIES: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type Measurement Input Type [Domain] Net proceeds received Sale of Stock, Consideration Received on Transaction Total operating expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Counterparty Name Counterparty Name [Domain] Beginning balance Ending balance Equity, Attributable to Parent Total other income Nonoperating Income (Expense) Equity investments Equity Securities, FV-NI, Current ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Insider Trading Policies and Procedures [Line Items] Other financing activities Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Contingent Consideration Obligation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Other revenue Other Revenue [Member] Other Revenue Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Gilead Sciences, Inc. Gilead Sciences, Inc. [Member] Gilead Sciences, Inc. Business Combination Business Combination [Domain] Vaccinal Antibody Grant Vaccinal Antibody Grant [Member] Vaccinal Antibody Grant [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Antidilutive shares excluded from calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Business Combination Business Combination [Axis] U.S. government agency bonds and discount notes U.S. government agency bonds and discount notes [Member] U.S. government agency bonds and discount notes [Member] Other non-cash items, net Adjustment To Reconcile Net Income To Cash Provided by (Used in) Operating Activity, Other Non-Cash Items, Net Adjustment To Reconcile Net Income To Cash Provided by (Used in) Operating Activity, Other Non-Cash Items, Net Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Percentage of commission rate from sale of shares (as a percent) Percentage Of Commission Rate From Sale Of Shares Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares. Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Plus: Cash deposits Cash Deposits Cash Deposits Net upfront payment Collaborative Arrangement, Amount Of Upfront Payment, Net Collaborative Arrangement, Amount Of Upfront Payment, Net Income Statement [Abstract] Income Statement [Abstract] STOCKHOLDERS’ EQUITY: Equity, Attributable to Parent [Abstract] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Maximum number of other infectious disease targets selected by VirBio Maximum Number Of Other Infectious Disease Targets Selected Maximum Number Of Other Infectious Disease Targets Selected Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Operating expenses: Operating Expenses [Abstract] Schedule of Loss Before Benefit From (Provision For) Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Total cash, cash equivalents and investments Cash, Cash Equivalents, And Investments Cash, Cash Equivalents, And Investments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Norgine Agreement Norgine Agreement [Member] Norgine Agreement Schedule of Assumptions Used for Estimating the Fair Value of Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Other Commitments [Domain] Other Commitments [Domain] City Area Code City Area Code Percentage of income eligible to receive Asset Acquisition, Percentage Of Income, Eligible To Receive Asset Acquisition, Percentage Of Income, Eligible To Receive Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Subsequent Event Subsequent Events [Text Block] Other R&D Research And Development, Other Research And Development, Other Schedule of Revenue from External Customers by Geographic Areas Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block] Name Forgone Recovery, Individual Name Contingent consideration obligation, noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Research and development Research and Development Expense [Abstract] TOTAL ASSETS Assets Pension actuarial gain Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Gross Unrealized Holding Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Awards Share-Based Payment Arrangement [Text Block] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Payroll and related expenses Accrued Payroll and Related Expense, Current Accrued Payroll and Related Expense, Current Other assets Increase (Decrease) in Other Operating Assets Adjustments of issuance costs and Issuance of common stock related to a follow-on public offering, net of issuance cost (in shares) Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Asset acquisition, milestone payment Asset Acquisition, Milestone Payment Asset Acquisition, Milestone Payment Other Other Customer [Member] Total stock-based compensation Share-Based Payment Arrangement, Expense Short-term investments Marketable Securities, Current Other long-term liabilities Other Liabilities, Noncurrent Goodwill Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Money market funds Money Market Funds [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Schedule of Estimated Fair Value of Significant Unobservable Inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized (loss) gain on investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Net loss per share, diluted (in USD per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Expected stock price volatility, maximum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Total Shareholder Return Amount Total Shareholder Return Amount Volatility Measurement Input Expected Revenue Volatility [Member] Measurement input expected revenue volatility. Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Research and development Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Change in estimated fair value of contingent consideration Change In Estimated Fair Value Of Contingent Consideration Change in estimated fair value of contingent consideration. CASH FLOWS FROM FINANCING ACTIVITIES: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net Total property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Securities contractual term (in years) Debt Securities, Available-for-Sale, Term Payment made from escrow account Asset Acquisition, Milestone Payment Made From Escrow Account Asset Acquisition, Milestone Payment Made From Escrow Account Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Unrecognized premium Grant Agreement, Unrecognized Premium Balance Grant Agreement, Unrecognized Premium Balance Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Adjustments of issuance costs and Issuance of common stock related to a follow-on public offering, net of issuance cost Stock Issued During Period, Value, New Issues Construction in progress Construction in Progress [Member] Risk-free interest rate, minimum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Segment Reporting [Table] Segment Reporting [Table] Research and development expenses Accrued Research And Development Expense, Current Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities. Computer equipment Computer Equipment [Member] Sale of Stock [Axis] Sale of Stock [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Balance at December 31, 2025 Balance at September 30, 2026 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Revenue Recognition [Abstract] Revenue Recognition [Abstract] First Si R N A Product H B V First Si R N A Product H B V [Member] First SiRNA product HBV. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Equity securities Equity Securities [Member] Corporate bonds Corporate Bond Securities [Member] Offering expenses Offering Cost, Expense Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Proceeds from equity investment Proceeds From Issuance of Common Stock in Connection With Collaboration Proceeds From Issuance of Common Stock in Connection With Collaboration. Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Less: Segment expenses Segment Expenses [Abstract] Segment Expenses Alnylam Agreement Alnylam Agreement [Member] Alnylam agreement. Public Offering Public Offering [Member] Public Offering Equity Components Equity Components [Axis] Amortized Cost Financial Assets Amortized Cost Basis Financial assets amortized cost basis. Product and Service Product and Service [Domain] Net cash paid for income tax Income Tax Paid, after Refund Received Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Aggregate offering price Sale Of Stock Consideration Aggregate Offering Price Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement. Change in fair value of equity investments Assets, Fair Value Adjustment Termination Date Trading Arrangement Termination Date Other Commitments [Axis] Other Commitments [Axis] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Property Plant And Equipment [Line Items] Property, Plant, and Equipment [Line Items] Licenses, collaborations and contingent consideration, net Research And Development, Licenses, Collaborations And Contingent Consideration Research And Development, Licenses, Collaborations And Contingent Consideration Subsequent Events [Abstract] Subsequent Events [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Non-cash restructuring, long-lived assets impairment and related charges Impairment, Long-Lived Asset, Held-For-Use And Disposal Gain (Loss) Impairment, Long-Lived Asset, Held-For-Use And Disposal Gain (Loss) Grant revenue Grant [Member] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Document Type Document Type Royalty payment obligation expiration period after first commercial sales (in years) Royalty Payment Obligation Expiration Period After First Commercial Sales Royalty payment obligation expiration period after first commercial sales. Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Maximum aggregate sales milestone payment Maximum Aggregate Sales Milestone Payment Maximum aggregate milestone payment for achievement of specified annual net sales Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Loss before benefit from (provision for) income taxes Loss before benefit from (provision for) income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 7) Commitments and Contingencies Total revenues Segment revenue Revenues Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Property and equipment, gross Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Unvested restricted shares Unvested Restricted Stock [Member] Unvested Restricted Stock Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Accrued interest receivable writeoff Debt Securities, Available-for-Sale, Accrued Interest Writeoff Furniture and fixtures Furniture and Fixtures [Member] Counterparty Name Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] All Award Types Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair Value Measurements Fair Value Disclosures [Text Block] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Expected term of options (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Maximum future development and regulatory milestone payments Asset Acquisition, Maximum Additional Future Development And Regulatory Milestone Payments Maximum additional future development and regulatory milestone payments under license agreement Payment received under license agreement Collaborative Arrangement, Payment Received Collaborative Arrangement, Payment Received PEO Name PEO Name Geographical [Axis] Geographical [Axis] Accrued and other liabilities Total accrued and other liabilities Accrued Liabilities and Other Liabilities Leasehold improvements Leasehold Improvements [Member] Common stock shares purchased (in shares) Common Stock, Shares Purchased Common Stock, Shares Purchased Reportable Segment Reportable Segment [Member] Reportable Segment Plus: Other segment items Segment Reporting, Other Segment Item, Amount Long-Lived Asset, Class Long-Lived Asset, Class [Axis] Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical and regulatory milestones [Member] Other assets Other Assets Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Fair value contingent consideration measurement input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Common stock, shares purchased price (in USD per share) Common Stock, Shares Purchased, Share Price Common Stock, Shares Purchased, Share Price Derivative Liability Liability Class [Axis] Maximum future development, regulatory and sales milestones payments Collaborative Arrangement, Maximum Future Development, Regulatory And Sales Milestones Payments Collaborative Arrangement, Maximum Future Development, Regulatory And Sales Milestone Payments Revenue Recognition Revenue [Policy Text Block] Cash, cash equivalents and restricted cash and cash equivalents at beginning of period Cash, cash equivalents and restricted cash and cash equivalents at end of period Total cash, cash equivalents and restricted cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Other professional and consulting expenses Accrued Professional Fees, Current Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Other accrued expenses Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Restricted cash and cash equivalents, current Restricted cash and cash equivalents, current Restricted Cash and Cash Equivalent, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Clinical costs Research And Development, Clinical Costs Research And Development, Clinical Costs Follow On Public Offering Follow On Public Offering [Member] Follow On Public Offering Customer [Domain] Customer [Domain] Net loss per share, basic (in USD per share) Earnings Per Share, Basic Measurement Input Type Measurement Input Type [Axis] Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Cost of revenue Cost of Revenue Sanofi Agreement Sanofi Agreement [Member] Sanofi Agreement Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Credit to research and development Collaborative Arrangement, Credit To Research And Development Collaborative Arrangement, Credit To Research And Development Accumulated deficit Retained Earnings (Accumulated Deficit) Maximum future development, regulatory and ex-US sales milestone payments Collaborative Arrangement, Maximum Future Development, Regulatory And Ex-US Sales Milestone Payments Collaborative Arrangement, Maximum Future Development, Regulatory And Ex-US Sales Milestone Payments Product and Service Product and Service [Axis] Equity securities Equity Securities, FV-NI Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Contingent consideration recognized Business Combination, Contingent Consideration, Liability Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Norgine Pharma UK Limited Norgine Pharma UK Limited [Member] Norgine Pharma UK Limited Cover [Abstract] Cover [Abstract] Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Foreign Non-US [Member] Expected dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Brent Sabatini [Member] Brent Sabatini Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Maximum milestone payment for achievement of specified development and regulatory milestones Maximum Milestone Payment For Achievement Of Specified Development And Regulatory Maximum Milestone Payment For Achievement Of Specified Development And Regulatory Equity Awards Adjustments Equity Awards Adjustments [Member] Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Options issued and outstanding Employee Stock Option Share-Based Payment Arrangement, Option [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class Asset Class [Axis] Proceeds from sale of equipment Proceeds from Sale of Machinery and Equipment Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Restricted cash and cash equivalents, noncurrent Restricted cash and cash equivalents, noncurrent Restricted Cash and Cash Equivalent, Noncurrent Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Other expense, net Other Nonoperating Income (Expense) Name Awards Close in Time to MNPI Disclosures, Individual Name Personnel Research And Development, Personnel Research And Development, Personnel Purchases of investments Payments to Acquire Investments Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Long-Lived Asset, Class Long-Lived Asset, Class [Domain] Fair Value by Liability Class Fair Value by Liability Class [Domain] Sale of stock (in USD per share) Sale of Stock, Price Per Share Business Combination, Contingent Consideration, Type Business Combination, Contingent Consideration, Type [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cost of revenue Cost Of Revenue, Net Of Royalties Cost Of Revenue, Net Of Royalties Schedule Of Property Plant And Equipment [Table] Property, Plant, and Equipment [Table] Probability of achievement Measurement Input Probability Rate [Member] Measurement input, probability rate. Preferred stock Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization consolidation and presentation of financial statements. Schedule of Accrued and Other Liabilities Schedule Of Accrued Liabilities And Other Liabilities [Table Text Block] Schedule Of Accrued Liabilities And Other Liabilities Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Payment of contingent consideration in excess of acquisition date fair value Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Grant Agreements Grant Agreements Disclosure [Text Block] Grant agreements disclosure. Manufacturing agreement Other Commitment Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Aggregate Fair Value Assets, Fair Value Disclosure Investments Investment, Policy [Policy Text Block] Contract manufacturing Research And Development, Contract Manufacturing Research And Development, Contract Manufacturing Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Upfront payment Asset Acquisition, Consideration Transferred, Upfront Payment Asset Acquisition Upfront Payment Other revenue Revenue Not from Contract with Customer Noncash lease expense Noncash Lease Expense Noncash lease expense. Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Company Selected Measure Amount Company Selected Measure Amount Change in fair value of equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Depreciation and amortization Depreciation, Depletion and Amortization Over-Allotment Over-Allotment [Member] Over-Allotment Excess funds payable under grant agreements Excess Funds Payable Under Grant Agreements Current Excess funds payable under grant agreements current. Entity Address, Address Line Two Entity Address, Address Line Two CURRENT ASSETS: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Obtaining a right-of-use asset in exchange for a lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Maximum commercial net sales-based milestone payments Asset Acquisition, Maximum Additional Commercial Net Sales Based Milestone Payments Maximum additional commercial net sales-based milestone payments under license agreement Benefit from (provision for) income taxes Benefit from (provision for) income taxes Income Tax Expense (Benefit) Award Timing Method Award Timing Method [Text Block] Net decrease in cash, cash equivalents and restricted cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc [Member] Alnylam Pharmaceuticals, Inc. Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Gates Foundation Gates Foundation [Member] Gates Foundation Expected stock price volatility, minimum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Accrued interest receivable Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss Net loss Net loss Net loss Segment and consolidated net loss Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location Location, Statement of Financial Position, Balance [Axis] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Vesting of restricted common stock Stock Issued During Period, Value, Restricted Stock Award, Gross Interest income Investment Income, Interest Discount on shares Common Stock, Discount on Shares Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Revenues: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Financial Support to Nonconsolidated Legal Entity Financial Support to Nonconsolidated Legal Entity [Domain]